# A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

> **NCT06640413** · PHASE1 · RECRUITING · sponsor: **Philogen S.p.A.** · enrollment: 56 (estimated)

## Conditions studied

- FAP

## Interventions

- **DRUG:** [177Lu]Lu-OncoFAP-23
- **DRUG:** L19IL2

## Key facts

- **NCT ID:** NCT06640413
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-31
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06640413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06640413, "A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06640413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*